Trial Profile
Randomized Study of Efficacy & Safety of Lapatinib & Epirubicin & Cyclophosphamide (EC90) Followed by Paclitaxel & Lapatinib Compared With EC90 Followed by Paclitaxel & Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- Acronyms ELATE
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 20 Dec 2021 This trial has been completed in Hungary (Global end date: 16 Dec 2010).
- 28 May 2019 This trial has been discontinued in Norway, according to European Clinical Trials Database.
- 02 May 2019 Trail was completed in France according to European Clinical Trials Database record. (global end date: 20 Jan 2011)